Core Insights - BioXcel Therapeutics is highlighted as a promising penny stock due to its late-stage pipeline progress, increasing market potential, and an upcoming FDA milestone, making it a company to watch for 2026 [1] Company Overview - BioXcel Therapeutics is a biopharmaceutical company that utilizes artificial intelligence (AI) and machine learning to discover and develop innovative treatments, particularly in neuroscience [2] - The company's lead product, IGALMI, is an FDA-approved sublingual film formulation of BXCL501 designed for the immediate treatment of severe agitation in individuals with schizophrenia and bipolar disorder [2] Regulatory Developments - BioXcel has conducted a Phase 3 SERENITY At-Home trial with 246 patients to evaluate the safety of BXCL501 in a home-use setting, collecting data on over 2,600 agitation episodes [3] - The trial results showed no discontinuations due to tolerability, no major adverse events related to the drug, and no new safety signals, prompting the company to submit a supplemental New Drug Application (sNDA) to the FDA for at-home use of IGALMI [3] - The company anticipates FDA approval within the year and is preparing for pre-launch and commercial activities [3] Market Potential - BioXcel is advancing its TRANQUILITY In-Care Phase 3 program to address agitation associated with Alzheimer's dementia, having received FDA feedback on the clinical protocol [4] - The company estimates that the at-home agitation market in the U.S. represents between 57 million and 77 million episodes annually, significantly higher than previous estimates of 23 million episodes [5] - If approved, at-home IGALMI could fulfill a substantial unmet need by transitioning treatment from institutional settings to patients' homes, benefiting the patients [5]

Core Insights - Oramed Pharmaceuticals has made significant advancements in its operations and strategic initiatives, focusing on long-term shareholder value creation [2][8] - The company has identified high-responder subgroups in its oral insulin program, showing potential for over 1% reduction in HbA1c, which enhances its regulatory and commercial positioning [4][17] - Oramed is pursuing a 60-patient trial in the U.S. to validate its oral insulin formulation, aiming for cost-effective evidence generation [5][17] Oral Insulin Program - The oral insulin program has shown promising results in high-responder subgroups, particularly among participants with lower BMI and older demographics [4] - A new U.S.-based trial is being initiated to validate the oral insulin formulation and refine patient selection criteria for future regulatory submissions [5] Investment Portfolio - Oramed has strategically invested in various biomedical companies, including a $99.5 million loan to Scilex Holdings, which has returned $95.5 million to date, with total expected returns of approximately $170 million [7][9] - The company invested $36.9 million in Alpha Tau Medical, with a current valuation of approximately $64.8 million, reflecting a gain of $27.1 million [9][10] - Oramed has also invested $7 million in BioXcel Therapeutics and $1.5 million in Pelthos Therapeutics, with significant gains realized in both investments [12][13] Growth Initiatives - The company is actively pursuing partnerships with strong companies to unlock market potential and drive value creation [15] - Oramed's diversified investment strategy has led to substantial returns while maintaining focus on its core oral insulin program [3][17] Financial Performance - As of September 30, 2025, Oramed's total cash and assets have grown to approximately $210 million, demonstrating effective capital deployment despite investing $17.8 million in R&D [16]

Core Viewpoint - Capricor Therapeutics' shares fell 33% following the FDA's issuance of a complete response letter (CRL) regarding the biologics license application (BLA) for deramiocel, intended to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][6] Regulatory Update - The FDA concluded its review of the BLA but could not approve it in its current form, citing a lack of substantial evidence of effectiveness and the need for additional clinical data [2][6] - The CRL also pointed out unresolved issues in the Chemistry, Manufacturing and Controls (CMC) section of the application, although management believes these concerns have been addressed in prior communications with the FDA [3][6] Market Reaction - The investor community was surprised by the CRL, especially since the FDA had previously accepted the BLA and granted it priority review in March, with a decision expected by August 31, 2025 [4][6] - Year-to-date, Capricor's shares have declined 44.7%, contrasting with a 0.9% decline in the industry [3] Future Plans - Capricor plans to engage in discussions with the FDA to clarify the issues raised in the CRL and to outline a regulatory path for deramiocel [6][7] - The BLA was based on data from the phase II HOPE-2 study and an open-label extension study, and a potential approval could have made deramiocel the first therapy for DMD cardiomyopathy [7]

Group 1: Earnings Performance - BioXcel Therapeutics reported a quarterly loss of $3.57 per share, which was better than the Zacks Consensus Estimate of a loss of $4.36, representing an earnings surprise of 18.12% [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The revenue for the quarter ended December 2024 was $0.37 million, exceeding the Zacks Consensus Estimate by 144%, although it was slightly down from $0.38 million a year ago [2] Group 2: Stock Performance and Outlook - BioXcel Therapeutics shares have declined approximately 63.6% since the beginning of the year, contrasting with the S&P 500's decline of 2.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$2.72 on revenues of $0.3 million, and for the current fiscal year, it is -$16.32 on revenues of $3.51 million [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which BioXcel Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Core Insights - BioXcel Therapeutics is advancing its SERENITY At-Home pivotal Phase 3 trial, with patient enrollment exceeding 60% of the required 200 patients for evaluating BXCL501 in treating agitation associated with bipolar disorders or schizophrenia [1][2][8] - The company has strengthened its cash position to approximately $35 million following a $14 million equity financing, which will support the SERENITY program [6][15] - Topline data from the SERENITY trial is expected in the second half of 2025, which may support a supplemental New Drug Application (sNDA) for label expansion of IGALMI in the at-home setting [1][2][8] Financial Performance - Net revenue from IGALMI for Q4 2024 was $366,000, a slight decrease from $376,000 in Q4 2023, while full-year revenue increased to $2.3 million from $1.4 million in 2023 [7][9] - Cost of Goods Sold (COGS) for Q4 2024 was $832,000, up from $714,000 in Q4 2023, primarily due to higher reserves for excess or obsolete inventory [10] - Research and Development (R&D) expenses decreased to $5.9 million in Q4 2024 from $9.9 million in Q4 2023, and full-year R&D expenses were $30.4 million, down from $84.3 million in 2023 [12] - Selling, General and Administrative (SG&A) expenses for Q4 2024 were $4.1 million, compared to $9.6 million in Q4 2023, with full-year SG&A expenses at $34.5 million, down from $83.4 million in 2023 [13][14] - The company reported a net loss of $10.9 million for Q4 2024, an improvement from a net loss of $22.3 million in Q4 2023, and a full-year net loss of $59.6 million compared to $179.1 million in 2023 [15] Clinical Programs - The SERENITY At-Home Phase 3 trial is designed as a double-blind, placebo-controlled study to evaluate the safety of a 120 mcg dose of BXCL501 for acute treatment of agitation in patients with bipolar disorders or schizophrenia [8][18] - The TRANQUILITY In-Care Phase 3 trial is also underway, focusing on the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer's dementia [19] - A Data Safety Monitoring Board (DSMB) is planned to assess safety during the SERENITY trial [8] Market Potential - The SERENITY program aims to address a significant unmet medical need, with an estimated 23 million episodes of agitation related to bipolar and schizophrenia occurring annually in the U.S. [2] - The company continues to supply IGALMI through existing distribution channels with minimal commercial support, indicating a focus on expanding market presence [5]

Core Insights - BioXcel Therapeutics, Inc. has successfully raised $14 million in equity financing, resulting in a cash position of approximately $35 million to support its clinical trials [1][2] - The company is advancing its SERENITY At-Home Phase 3 trial, which aims to evaluate the safety of BXCL501 for treating agitation associated with bipolar disorders or schizophrenia in a home setting [1][3] - Topline data from the trial is expected in the second half of 2025, which may support a supplemental New Drug Application (sNDA) for expanding the label of IGALMI for at-home use [2][3] Company Overview - BioXcel Therapeutics is a biopharmaceutical company focused on developing transformative medicines in neuroscience using artificial intelligence [1][13] - The company’s investigational product, BXCL501, is an orally dissolving film formulation of dexmedetomidine, currently under investigation for various indications including agitation associated with Alzheimer's dementia and bipolar disorders [12][13] - IGALMI (dexmedetomidine) is a prescription medicine used for the acute treatment of agitation in adults with schizophrenia and bipolar disorder [4][12] SERENITY At-Home Phase 3 Trial - The trial is a double-blind, placebo-controlled study enrolling 200 patients with a history of agitation episodes, who will self-administer BXCL501 or placebo during the trial [3] - Safety data will be collected throughout the 12-week trial period, with exploratory endpoints including modified global impression scales to assess treatment effectiveness [3] Financial Position - Following the recent equity financing, the company is well-positioned financially with $35 million in cash to support ongoing clinical trials and operational needs [1][2]

Core Insights - BioXcel Therapeutics is progressing with its SERENITY At-Home trial, having reached 33% enrollment of the targeted 200 patients, aimed at evaluating the safety of BXCL501 for treating agitation associated with bipolar disorders or schizophrenia in a home setting [1][2][3] - Topline data results are anticipated in the second half of 2025, which will support a potential supplemental new drug application (sNDA) for expanding the label of IGALMI [1][3] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative medicines in neuroscience using artificial intelligence [13] - The company’s approach involves leveraging existing approved drugs and big data to identify new therapeutic indications [13] SERENITY At-Home Trial Details - The SERENITY At-Home trial is a double-blind, placebo-controlled study assessing the safety of a 120 mcg dose of BXCL501 for acute treatment of agitation in home settings [4] - The trial will collect safety data over a 12-week period, with patients self-administering the drug during agitation episodes [4] Market Context - There are approximately 23 million annual episodes of agitation related to bipolar disorders or schizophrenia occurring in the U.S. home setting, with no FDA-approved therapies currently available for acute treatment in this context [3][4]

Core Insights - BioXcel Therapeutics is progressing with its SERENITY At-Home trial, which is pivotal for evaluating the safety of BXCL501 in treating agitation associated with bipolar disorders or schizophrenia in a home setting [1][2][4] - The trial aims to enroll 200 patients and has reached 33% enrollment, with topline data expected in the second half of 2025 to support a potential supplemental new drug application (sNDA) for IGALMI® [1][3][4] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative medicines in neuroscience using artificial intelligence [13] - The company’s investigational product, BXCL501, is an orally dissolving film formulation of dexmedetomidine, currently under investigation for various indications including agitation associated with Alzheimer's dementia and bipolar disorders [12][13] Trial Details - The SERENITY At-Home trial is a double-blind, placebo-controlled study assessing the safety of a 120 mcg dose of BXCL501 for acute treatment of agitation [4] - The trial is designed for patients with a history of agitation episodes, allowing them to self-administer the treatment during episodes over a 12-week period [4] Market Context - There are an estimated 23 million annual episodes of agitation associated with bipolar disorders or schizophrenia occurring in the home setting in the U.S., with no FDA-approved therapies currently available for acute treatment in this context [3][4] - The SERENITY At-Home trial represents a significant opportunity for BioXcel to address an unmet medical need in the treatment of agitation [3]

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to ...

Core Viewpoint - The market anticipates BioXcel Therapeutics, Inc. (BTAI) to report a year-over-year increase in earnings despite lower revenues for the quarter ended December 2024, with actual results being crucial for stock price movement [1][2]. Financial Expectations - The consensus EPS estimate for BioXcel Therapeutics is a loss of $4.36 per share, reflecting a year-over-year change of +64.1% [3]. - Expected revenues are projected at $0.15 million, which is a decrease of 60.5% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for BioXcel is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -15.50%, suggesting a bearish sentiment among analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a strong predictive power for positive readings [7][8]. - BioXcel's current Zacks Rank is 2 (Buy), but the negative Earnings ESP complicates predictions for an earnings beat [11]. Historical Performance - In the last reported quarter, BioXcel was expected to post a loss of $8 per share but delivered a loss of $5.12, resulting in a surprise of +36% [12]. - Over the past four quarters, BioXcel has beaten consensus EPS estimates three times [13]. Industry Comparison - Another company in the same industry, IGM Biosciences, Inc. (IGMS), is expected to report a loss of $0.72 per share, with revenues projected at $0.53 million, down 18.5% year-over-year [17]. - IGM has an Earnings ESP of 4.55% and a Zacks Rank of 2, indicating a higher likelihood of beating consensus EPS estimates [18].